Swiss industrial holding whose main unit, Belimed, makes hospital sterilization and disinfection equipment.
Swiss industrial holding whose main unit, Belimed, makes hospital sterilization and disinfection equipment.
Belimed sells washer-disinfectors and sterilisers to hospitals and pharma plants, often through tenders, so large orders are lumpy. Installed machines then generate parts and maintenance revenue, which is steadier than equipment sales.
In one line: A small Swiss Steris.
Moat: narrow (installed base, regulatory licence). Regulated hospital sterilization equipment has long replacement cycles and service contracts.
Headquarters: Zug, Switzerland · Employees: 913
Size Metall Zug (METN.SW) is a Switzerland Health Care company (Medical Specialties) with a market value of $2.19B, the 88th largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 839.00 on 18 Nov 2026.
Performance Over six months the shares gained 19.5%, against -0.1% for the median peer and +9.3% for the Switzerland market (cap-weighted) — 6th highest of 20 in its peer set.
Growth Revenue fell 0.3% over the last twelve months (peer median +7.5%); the operating margin is -9.5% (peer median 15.2%).
Valuation It trades at 139.8× forward earnings against a peer median of 22.6× (most expensive of 19).
Capital Return on invested capital runs 7.4 points below its cost of capital (5.0% WACC).
Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CHF 196M | CHF 195M | CHF 283M | CHF 495M | CHF 646M |
| Revenue growth | — | -31% | -43% | -23% | — |
| Gross profit | CHF 63.0M | CHF 61.4M | CHF 90.9M | CHF 151M | CHF 227M |
| EBITDA | -CHF 9.56M | -CHF 17.5M | -CHF 14.0M | CHF 10.8M | CHF 50.4M |
| Net income | -CHF 10.8M | -CHF 15.2M | CHF 52.6M | CHF 21.6M | CHF 130M |
| Free cash flow | -CHF 43.0M | -CHF 48.2M | -CHF 25.0M | -CHF 18.8M | -CHF 39.0M |
| Capital expenditure | CHF 52.8M | CHF 45.5M | CHF 33.9M | CHF 36.2M | CHF 34.8M |
| Total debt | n/a | CHF 154M | CHF 82.8M | CHF 36.6M | CHF 17.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Metall Zug METN.SW | $2.19B | +20% | 0% | -10% | 139.8× | n/a |
| Steris STE | $25.2B | +21% | +8% | 20% | 21.9× | 14.0% |
| Getinge GETI-B.ST | $7.45B | +40% | -4% | 14% | 21.1× | 5.0% |
| Shinva Medical Instrument 600587.SS | $1.10B | -10% | +6% | 5% | 13.4× | -6.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | METN.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.9% | -1.4% | 11th highest of 21 |
| 6-month return | +19.5% | -0.1% | 6th highest of 20 |
| Distance from 52-week high | -5.5% | -24.0% | 2nd highest of 21 |
| Revenue growth (TTM) | -0.3% | +7.5% | 4th lowest of 21 |
| Operating margin | -9.5% | 15.2% | lowest of 21 |
| Forward P/E | 139.8× | 22.6× | most expensive of 19 |
| ROIC minus cost of capital | -7.4 pp | +3.5 pp | 4th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Metall Zug METN.SW | Switzerland | $2.19B | +20% | 0% | -10% | 139.8× | n/a | n/a |
| Draegerwerk AG & Co. KGaA DRW8.DE | Germany | $2.13B | +25% | +5% | 7% | 10.2× | -10.2% | +0.4% |
| Shanghai Conant Optical 2276.HK | Hong Kong | $2.25B | -17% | +8% | 29% | 22.1× | -1.1% | +14.1% |
| JEOL 6951.T | Japan | $2.12B | -2% | -15% | 12% | 15.5× | 22.2% | +10.2% |
| Establishment Labs ESTA | United States | $2.11B | +1% | +38% | -7% | n/a | n/a | n/a |
| Veracyte VCYT | United States | $2.06B | -43% | +18% | 16% | 17.1× | 18.0% | +34.5% |
| Bonesupport BONEX.ST | Sweden | $2.06B | +21% | +25% | 25% | 61.5× | 12.6% | +45.4% |
| Micro-Tech (Nanjing) 688029.SS | China | $2.33B | 0% | +6% | 18% | 28.1× | 11.9% | +19.2% |
| Elekta EKTA-B.ST | Sweden | $2.35B | 0% | -7% | 6% | 15.3× | 10.7% | +4.0% |
| Jafron Biomedical 300529.SZ | China | $2.35B | +3% | +1% | 37% | 24.3× | 6.1% | +0.6% |
| Neogen NEOG | United States | $2.42B | +25% | 0% | 0% | 32.6× | n/a | n/a |
| Double Medical Technology 002901.SZ | China | $2.43B | -2% | +13% | 26% | 24.2× | 7.6% | +10.4% |
| Medacta MOVE.SW | Switzerland | $2.48B | -28% | +8% | 15% | 24.0× | n/a | n/a |
| EBOS EBO.AX | Australia | $2.50B | +7% | +3% | 3% | 15.7× | 4.7% | +6.8% |
| Medartis MED.SW | Switzerland | $1.86B | +47% | +30% | 2% | 72.8× | n/a | n/a |
| SKAN SKAN.SW | Switzerland | $1.85B | +40% | +9% | 11% | 49.5× | 13.8% | +11.7% |
| Molbio Diagnostics MOLBIO.NS | India | $1.85B | n/a | +35% | 17% | n/a | n/a | n/a |
| Rigaku 268A.T | Japan | $1.85B | -54% | +9% | 16% | 23.1× | 18.3% | +14.5% |
| Fukuda Denshi 6960.T | Japan | $1.84B | +4% | 0% | 19% | 15.4× | -1.6% | -1.0% |
| Shandong Weigao Group Medical Polymer 1066.HK | Hong Kong | $1.82B | -8% | +7% | 14% | 8.2× | -12.6% | +2.1% |
| Ottobock SE & Co. KGaA OBCK.DE | Germany | $2.65B | -30% | +5% | 17% | 12.3× | -1.2% | +8.0% |